In advanced prostate cancer (PCa), the effect of anti-PD-1 checkpoint blockade has been disappointing, with just 5–10% of tumors that exhibit defects in microsatellite instability (MSI) pathways [7] or CDK12 biallelic mutations responding to this therapy [8]. The gene discussed is CDK12; the disease is posterior cortical atrophy.